2025年9月19日,劲方医药科技(上海)股份有限公司(以下简称劲方医药,2595.HK)成功于香港联交所主板上市,超额配售权行使前发行规模2.33亿美元,超额配售权行使后达2.68亿美元,其中,基石投资者投资规模1亿美元。中信证券担任独家保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。中信证券全球投资银行管理委员会联席主任程杰、全球投资银行管理委员会委员于杨出席上市仪式。项目...
Source Link2025年9月19日,劲方医药科技(上海)股份有限公司(以下简称劲方医药,2595.HK)成功于香港联交所主板上市,超额配售权行使前发行规模2.33亿美元,超额配售权行使后达2.68亿美元,其中,基石投资者投资规模1亿美元。中信证券担任独家保荐人、整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人。中信证券全球投资银行管理委员会联席主任程杰、全球投资银行管理委员会委员于杨出席上市仪式。项目...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.